Nicotinamide adenine dinucleotide (NAD+) occupies a unique position in biochemistry: it is simultaneously one of the most fundamental metabolic cofactors in every living cell and one of the most actively researched targets in aging biology. The compound role in cellular energy production has been understood since the early twentieth century, but its emergence as a focus of longevity research is a development of the past two decades.
The NAD+ Decline Hypothesis
The core observation driving NAD+ longevity research is straightforward: intracellular NAD+ levels decline with age. This has been measured in multiple tissues across multiple species, including humans. A 2016 study published in Cell Metabolism by Camacho-Pereira and colleagues demonstrated a roughly fifty percent decline in NAD+ levels in aged mice compared to young controls, with corresponding decreases in mitochondrial function and increases in markers of cellular stress.
The decline appears to be driven by both decreased synthesis (particularly through the salvage pathway enzyme NAMPT) and increased consumption (primarily by CD38, a NAD+-consuming enzyme that increases with age and inflammation). The net result is a cellular energy deficit that compounds over time, affecting every NAD+-dependent process — from DNA repair to mitochondrial respiration to sirtuin-mediated gene regulation.
Sirtuins: The NAD+-Dependent Regulators
Much of the excitement around NAD+ in aging research traces back to sirtuins — a family of NAD+-dependent deacylase enzymes. In mammals, there are seven sirtuins (SIRT1 through SIRT7), each with distinct subcellular localizations and substrate preferences. SIRT1 and SIRT3 have received the most attention in longevity research.
Sirtuins require NAD+ as a co-substrate (not just a cofactor — they consume it stoichiometrically). When NAD+ levels fall, sirtuin activity decreases, and the downstream processes they regulate — including mitochondrial biogenesis, inflammatory responses, DNA repair, and circadian rhythm maintenance — are compromised. The theory is that restoring NAD+ levels could restore sirtuin function and, by extension, cellular resilience.
Preclinical Results
Studies using NAD+ precursors (NMN and NR) in mouse models have reported improvements in glucose tolerance, endurance capacity, vascular function, and stem cell function in aged animals. A landmark 2013 study by Gomes and colleagues showed that short-term NMN treatment in twenty-two-month-old mice restored NAD+ levels and mitochondrial function to levels comparable to six-month-old controls — at least by the measured biomarkers.
More recent work has explored direct NAD+ supplementation, bypassing the precursor step entirely. Injectable NAD+ achieves rapid intracellular uptake and has been used in animal studies to investigate acute metabolic effects, neuroprotective properties, and post-injury recovery. The pharmacokinetics differ substantially from oral precursors, which must be absorbed, metabolized, and converted before reaching target tissues.
Limitations and Open Questions
It is important to note that the human clinical trial landscape for NAD+ and its precursors is still young. Several phase I and phase II trials have demonstrated safety and measurable increases in blood NAD+ levels, but clinically meaningful endpoints (reduced disease incidence, improved physical function, extended healthspan) have not yet been established in randomized controlled trials.
There are also unanswered questions about optimal dosing, timing, tissue-specific delivery, and whether raising NAD+ levels uniformly across all tissues is desirable. Some researchers have raised concerns about potential cancer cell exploitation of elevated NAD+ — rapidly dividing cells also depend on NAD+ for their metabolism, though the evidence on this point is mixed.
Quality and Supply
Research-grade NAD+ is supplied as a lyophilized powder and should be stored at negative twenty degrees Celsius. Reconstitute with bacteriostatic water for injection studies. Purity of ninety-eight percent or higher by HPLC is standard, with mass spectrometry identity confirmation. Universal Amino Goods supplies NAD+ in both 500mg and 1000mg quantities, each with a third-party certificate of analysis.
For researchers investigating aging biology, metabolic function, or mitochondrial health, NAD+ remains one of the most tractable targets — well-characterized, broadly studied, and backed by a substantial preclinical evidence base.